| Similar Articles |
|---|
 |
The Motley Fool
October 27, 2006
Brian Lawler |
Wake Up to Sepracor Its insomnia drug is taking hold, and sales of its other drug jumped, too. If Sepracor can slim down its marketing spending, earnings should skyrocket. Investors, take note.   |
The Motley Fool
July 21, 2006
Brian Lawler |
Sepracor Stays Alert Insomnia drug Lunesta's sales growth is anything but sleepy. Despite the shares' ups and downs, Sepracor's most recent earnings suggest that its performance remains admirably steady. |
BusinessWeek
June 11, 2007
Mara Der Hovanesian |
Why Seprecor May Surprise The Naysayers Sentiment is mixed on Wall Street about Sepracor, the Marlborough pharmaceutical best known for its sleep drug, Lunesta. |
The Motley Fool
September 12, 2007
Brian Orelli |
Butterflies Move Eastward Sepracor and GlaxoSmithKline ink a deal to market Lunesta worldwide. The market in Europe for sleep aids last year was about $500 million, but only about a quarter of insomnia sufferers are on medication, so there's certainly room for the market to grow. |
The Motley Fool
December 17, 2004
Brian Gorman |
Sepracor's Dream Drug? Investors should be awake to Lunesta's potential pitfalls. |
The Motley Fool
February 17, 2005
Karl Thiel |
Sleeping on Neurocrine's Shares Why haven't Neurocrine Biosciences shares moved? It's partly history, with delays in getting an insomnia drug to market. |
The Motley Fool
July 30, 2007
Brian Orelli |
Why Sepracor Investors Can't Sleep Shares of the drug maker were hammered after the company announced lower than expected earnings and a not so bright future. |
The Motley Fool
October 26, 2004
Charly Travers |
Sepracor's Tough Road to Profits Will insomnia drug Estorra take the company to the promised land? |
BusinessWeek
January 17, 2005
Weintraub & Barrett |
Waking Up The Insomnia Market On Dec. 16, Sepracor Inc. won approval from the Food & Drug Administration to market Lunesta, a new sleep aid. Giddy investors pushed Sepracor's stock up 16%, to $60, in the two weeks following the news. |
The Motley Fool
November 17, 2006
Billy Fisher |
Vanda Shareholders Sleeping Better The latest news on the company's insomnia drug boosts the stock. |
The Motley Fool
October 31, 2007
Brian Orelli |
A Slimmer Sepracor The big-pharma company reduces its sales team after a government decision forces price cuts for one of its top drugs. Investors, take note. |
The Motley Fool
May 8, 2007
Brian Lawler |
Neurocrine Is Waking Up After being put to sleep for much of 2006 following an unexpected FDA smackdown on its lead drug, indiplon, shares of the biopharma have boosted over 50% higher versus its lows last year. |
BusinessWeek
May 31, 2004
Gene G. Marcial |
Seeking Sepracor? Sepracor is takeover bait because it is just what Big Pharma wants: diversified drugs and the newly approved sleep-disorder medication with blockbuster potential, Estorra. |
The Motley Fool
May 2, 2008
Brian Orelli |
Sepracor Diversifies to Sleep Better With its two top drugs in decline, diversification was the only answer for Sepracor. |
The Motley Fool
October 30, 2007
Brian Orelli |
Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note. |
The Motley Fool
December 14, 2007
Brian Lawler |
FDA Knocks Neurocrine a Knuckle Sandwich The FDA clobbers drugmaker Neurocrine with another delay. |
The Motley Fool
March 9, 2004
David Nierengarten |
Sepracor's No Sleeper FDA approval for its sleeping medication sends Sepracor's stock up 70%. |
The Motley Fool
August 1, 2007
Brian Lawler |
Neurocrine Awaits Its Destiny Neurocrine Biosciences updates investors on its plans for the rest of the year. A new marketing application was submitted for lead drug indiplon, following a negative FDA decision last year. Good news could come as soon as December 2007. |
The Motley Fool
June 27, 2008
Brian Lawler |
Vanda's Drug Draws a Yawn Shares of Vanda Pharmaceuticals have fallen more than 20% recently, even though the company said that its phase 3 clinical trial met its primary goal. |
The Motley Fool
September 5, 2006
Brian Lawler |
Neurocrine Wakes Up Indiplon The biotech company announces new drug delays. Investors, take note. |
The Motley Fool
September 26, 2007
Billy Fisher |
More Than 40 Winks From Arena The company announced positive preliminary results from its phase 2 clinical trial for APD125, which aims to treat people suffering from chronic insomnia. Investors, take note. |
The Motley Fool
July 24, 2006
Stephen D. Simpson |
Can Schering-Plough Continue to Shine? Cost-cutting and cholesterol drug sales continue apace, but is the company vulnerable? Investors, take note. |
The Motley Fool
January 24, 2007
Brian Lawler |
Neurocrine in the Green 2006 wasn't kind to the drug developer, but whatever happens with indiplon, Neurocrine's management deserves kudos for keeping investors well informed on the status of the drug and where the company stands as far as timelines go. |
ifeminists
September 14, 2005
Tony Zizza |
Lunesta Lunacy Big Pharma will not stop telling us that we need countless prescription medicines to treat all that troubles us unless we actually take the time to listen to what we're being told. To believe that as adults we need Lunesta to cope with electric bills is lunacy. |
The Motley Fool
August 30, 2004
Charly Travers |
It's a Hard-Knock Market You can never eliminate the risk in investing, but you can manage risk by understanding where you're putting your money. |
BusinessWeek
April 23, 2007
Alex Halperin |
Vioxx Casts A Long, Long Shadow More than two years after Merck & Co. pulled its Vioxx painkiller from shelves over heart attack and stroke risks, the Food & Drug Administration is still skittish about the safety of drugs currently on the market and those coming up for review. |
The Motley Fool
October 18, 2004
Charly Travers |
Biotech's 5-Baggers How can yesterday's biotech winners lead you to today's top performers? |
